Singapore-based biotechnology startup Mirxes saw its losses swell to about $70 million in 2023, a 25% rise from a year earlier, even as its revenue increased 36% during the year.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
